#Israel #Tel Aviv #RedHill Biopharma #Opaganib #Ebola Virus

RedHill Biopharma's Fight Against Ebola Virus Disease

The current outbreak of Ebola Virus Disease (EVD), fueled by the rare Bundibugyo ebolavirus subtype, poses a significant threat as there are no approved medications or vaccines available. In this critical scenario, RedHill Biopharma is making strides to advance its investigational oral drug, opaganib, to combat this deadly disease.

Partnership with Global Health Authorities

RedHill Biopharma has engaged in discussions with potential collaborators, including the World Health Organization (WHO), to facilitate the clinical advancement of opaganib. This includes the integration of opaganib into the WHO’s SOLIDARITY CORE clinical trial platform, aimed at establishing more effective treatment options for patients.

Opaganib's Mechanism of Action

Opaganib functions as a sphingosine kinase 2 (SPHK2) inhibitor, targeting crucial cellular mechanisms that HIV and EVD exploit to invade host cells. This dual mechanism presents a unique opportunity to develop a more comprehensive approach to infectious disease management. Specifically, opaganib affects the PI3K/Akt pathway, which plays a pivotal role in viral entry, while also suppressing key inflammatory pathways.

Promising Clinical Outcomes

In a Phase 3 study examining its antiviral activity in severe COVID-19 cases, opaganib showed a remarkable 70.2% reduction in mortality when administered alongside the best available standard of care, demonstrating its potential efficacy against serious viral infections. Furthermore, preclinical studies have confirmed opaganib's effectiveness against EVD, showcasing increased survival rates in animal models.

Safety and Tolerability

Safety is paramount in drug development, and opaganib has demonstrated a reassuring safety and tolerability profile across 470 trial participants. The drug’s design facilitates oral administration, easing storage and distribution challenges often faced during outbreaks, which could be instrumental in enhancing global infectious disease preparedness.

The Vision for Biodefense

Gilead Raday, COO of RedHill Biopharma, noted the urgency of strengthening biodefense infrastructures globally. The ability to administer opaganib alongside other direct-acting antivirals offers the potential for a layered therapeutic strategy to tackle EVD effectively. This host-directed therapy aligns with contemporary efforts to revamp infectious disease response mechanisms worldwide.

Future Directions

While regulatory approval of opaganib remains an objective, its clinical exploration is crucial amidst escalating global health threats. RedHill Biopharma has proactively provided relevant entities with information regarding the safety and efficacy profile of opaganib to support rapid discussions around its deployment in combatting Ebola.

The use of investigational drugs in outbreak situations like the current EVD crisis is a compelling reminder of the necessity for ongoing innovation, collaboration, and readiness in addressing infectious disease threats. RedHill Biopharma stands at the forefront of this challenge, committed to providing hope in such dire circumstances.